GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF SummitGlobeNewsWire · Sep 28, 2026
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research · Sep 14, 2026
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To BuyBenzinga · Sep 14, 2026
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic PillarsGlobeNewsWire · Sep 8, 2026
GRI Bio Featured in "Why Now" On-Demand Video WebcastGlobeNewsWire · Aug 27, 2026
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026GlobeNewsWire · Aug 24, 2026GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$1.19 | -$0.91 | Beat |
| May 13, 2026 | -$0.91 | -$1.61 | Miss |
| Mar 13, 2026 | -$29.27 | -$13.25 | Beat |
| Nov 14, 2025 | -$29.26 | -$35.85 | Miss |
| Aug 14, 2025 | -$36.69 | -$36.69 | Beat |
| Aug 12, 2025 | -$1.31 | -$162.40 | Miss |